Repligen (NASDAQ:RGEN) Upgraded by StockNews.com to “Hold” Rating

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a research note published on Friday.

RGEN has been the subject of a number of other research reports. JPMorgan Chase & Co. increased their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Evercore ISI began coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price target for the company. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. Royal Bank of Canada lifted their price objective on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a report on Friday, February 21st. Finally, Canaccord Genuity Group upped their target price on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and a consensus price target of $178.64.

Repligen Trading Down 8.0 %

Shares of Repligen stock opened at $111.94 on Friday. The firm has a market cap of $6.29 billion, a price-to-earnings ratio of -219.49, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. Repligen has a 52-week low of $106.78 and a 52-week high of $182.52. The company’s 50-day simple moving average is $150.03 and its 200-day simple moving average is $147.51. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. As a group, equities research analysts anticipate that Repligen will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

A number of institutional investors have recently bought and sold shares of the stock. Cerity Partners LLC grew its stake in shares of Repligen by 90.0% during the 3rd quarter. Cerity Partners LLC now owns 5,541 shares of the biotechnology company’s stock valued at $825,000 after buying an additional 2,625 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Repligen by 12.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,525 shares of the biotechnology company’s stock valued at $1,418,000 after acquiring an additional 1,032 shares during the last quarter. Verition Fund Management LLC increased its stake in Repligen by 114.7% during the third quarter. Verition Fund Management LLC now owns 5,690 shares of the biotechnology company’s stock worth $847,000 after acquiring an additional 3,040 shares during the last quarter. Janus Henderson Group PLC increased its stake in Repligen by 848.4% during the third quarter. Janus Henderson Group PLC now owns 23,700 shares of the biotechnology company’s stock worth $3,528,000 after acquiring an additional 21,201 shares during the last quarter. Finally, IHT Wealth Management LLC purchased a new position in shares of Repligen in the 3rd quarter worth about $407,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.